Peroxisome proliferator-activated receptor-δ as emerging target in liver disease

Drug Development Research

Volumn 71, Issue 2, 2010, Pages 106-111

  Schnabl, Bernd ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Chronic liver disease; Hepatic steatohepatitis; Hepatic steatosis; Liver fibrosis; Metabolic syndrome; PPAR

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; GW 590735; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST;

BLOOD TOXICITY; CHRONIC DISEASE; CLINICAL TRIAL; DRUG SAFETY; FATTY LIVER; GLUCOSE HOMEOSTASIS; HEPATITIS; HUMAN; INSULIN RESISTANCE; LIVER CELL; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER INJURY; LIVER PROTECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; NEPHROTOXICITY; NEUTROPHIL CHEMOTAXIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROGNOSIS; PROTEIN FUNCTION; REVIEW; TECHNOLOGY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77951571902     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20358     Document Type: Review

References (44)

1. Albanis E, Friedman SL. 2006. Antifibrotic agents for liver disease. Am J Transplant 6:12-19.
2. Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, Boland R, Evans RM. 2002. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA 99:303-308. (Pubitemid 34060358)
3. Bataller R, Brenner DA. 2005. Liver fibrosis. J Clin Invest 115:209-218.
4. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. 2006. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355:2297-2307. (Pubitemid 44837778)
5. Borkham-Kamphorst E, Meurer SK, Gressner AM, Weiskirchen R. 2005. Disruption of intermolecular disulfide bonds in PDGF-BB dimers by N-acetyl-L-cysteine does not prevent PDGF signaling in cultured hepatic stellate cells. Biochem Biophys Res Commun 338:1711-1718. (Pubitemid 41643080)
6. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, et al. 2008. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359:2429-2441.
7. Gabbay E, Zigmond E, Pappo O, Hemed N, Rowe M, Zabrecky G, Cohen R, Ilan Y. 2007. Antioxidant therapy for chronic hepatitis C after failure of interferon: results of phase II randomized, double-blind placebo controlled clinical trial. World J Gastroenterol 13:5317-5323. (Pubitemid 47559461)
8. Gebhardt R. 2002. Oxidative stress, plant-derived antioxidants and liver fibrosis. Planta Med 68:289-296. (Pubitemid 34494036)
9. Gines P, Cardenas A, Arroyo V, Rodes J. 2004. Management of cirrhosis and ascites. N Engl J Med 350:1646-1654.
10. Girroir EE, Hollingshead HE, He P, Zhu B, Perdew GH, Peters JM. 2008. Quantitative expression patterns of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) protein in mice. Biochem Biophys Res Commun 371:456-461.
11. Hellemans K, Michalik L, Dittie A, Knorr A, Rombouts K, De Jong J, Heirman C, Quartier E, Schuit F, Wahli W, et al. 2003. Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 124:184-201. (Pubitemid 36055351)
12. Kang K, Reilly SM, Karabacak V, Gangl MR, Fitzgerald K, Hatano B, Lee CH. 2008. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab 7:485-495. (Pubitemid 351729204)
13. Kino T, Rice KC, Chrousos GP. 2007. The PPARdelta agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition. Eur J Clin Invest 37:425-433. (Pubitemid 46653139)
14. Knight B, Yeap BB, Yeoh GC, Olynyk JK. 2005. Inhibition of adult liver progenitor (oval) cell growth and viability by an agonist of the peroxisome proliferator activated receptor (PPAR) family member gamma, but not alpha or delta. Carcinogenesis 26:1782-1792.
15. Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM, Gonzalez FJ, Ham J, Kang H, Peters JM, et al. 2006. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 103:3444-3449. (Pubitemid 43346488)
16. -/- bone marrow. J Lipid Res 50:214-224.
17. Nagasawa T, Inada Y, Nakano S, Tamura T, Takahashi T, Maruyama K, Yamazaki Y, Kuroda J, Shibata N. 2006. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 536:182-191.
18. Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, et al. 2008. AMPK and PPARdelta agonists are exercise mimetics. Cell 134:405-415.
19. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. 2003. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38:1008-1017. (Pubitemid 37221684)
20. Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A, Vats D, Morel CR, Goforth MH, Subramanian V, Mukundan L, Ferrante AW, Chawla A. 2008. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab 7:496-507. (Pubitemid 351729205)
21. Pang M, de la Monte SM, Longato L, Tong M, He J, Chaudhry R, Duan K, Ouh J, Wands JR. 2009. PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J Hepatol 50:1192-1201.
22. Peraza MA, Burdick AD, Marin HE, Gonzalez FJ, Peters JM. 2006. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol Sci 90:269-295.
23. Peters JM, Gonzalez FJ. 2009. Sorting out the functional role(s) of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in cell proliferation and cancer. Biochim Biophys Acta 1796:230-241.
24. Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, Everett C, Reitman ML, Hudson LD, Gonzalez FJ. 2000. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator- activated receptor beta(delta). Mol Cell Biol 20:5119-5128. (Pubitemid 30431565)
25. Pollard JW. 2009. Trophic macrophages in development and disease. Nat Rev Immunol 9:259-270.
26. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. 2002. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122:1303-1313. (Pubitemid 34465173)
27. Qin X, Xie X, Fan Y, Tian J, Guan Y, Wang X, Zhu Y, Wang N. 2008. Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice. Hepatology 48:432-441.
28. Reilly SM, Lee CH. 2008. PPAR delta as a therapeutic target in metabolic disease. FEBS Lett 582:26-31. (Pubitemid 350297247)
29. Rimola A, Londono MC, Guevara G, Bruguera M, Navasa M, Forns X, Garcia-Retortillo M, Garcia-Valdecasas JC, Rodes J. 2004. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 78:686-691. (Pubitemid 39244729)
30. Riserus U, Sprecher D, Johnson T, Olson E, Hirschberg S, Liu A, Fang Z, Hegde P, Richards D, Sarov-Blat L, et al. 2008. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 57:332-339.
31. Rockey DC. 2008. Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis 12:939-962, xi.
32. Schenk S, Saberi M, Olefsky JM. 2008. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 118:2992-3002.
33. Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA, Brenner DA. 2001. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology 34:89-100. (Pubitemid 32591487)
34. Schnabl B, Purbeck CA, Choi YH, Hagedorn CH, Brenner DA. 2003. Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology 37:653-664. (Pubitemid 36258787)
35. Schnabl B, Scholten D, Brenner DA. 2008. What is the potential role of antifibrotic agents for the treatment of liver disease? Nat Clin Pract Gastroenterol Hepatol 5:496-497.
36. Schuler M, Ali F, Chambon C, Duteil D, Bornert JM, Tardivel A, Desvergne B, Wahli W, Chambon P, Metzger D. 2006. PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metab 4:407-414. (Pubitemid 44645068)
37. Shan W, Nicol CJ, Ito S, Bility MT, Kennett MJ, Ward JM, Gonzalez FJ, Peters JM. 2008a. Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice. Hepatology 47:225-235. (Pubitemid 351171060)
38. Shan W, Palkar PS, Murray IA, McDevitt EI, Kennett MJ, Kang BH, Isom HC, Perdew GH, Gonzalez FJ, Peters JM. 2008b. Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. Toxicol Sci 105:418-428.
39. Shearer BG, Billin AN. 2007. The next generation of PPAR drugs: do we have the tools to find them? Biochim Biophys Acta 1771:1082-1093.
40. Sprecher DL, Massien C, Pearce G, Billin AN, Perlstein I, Willson TM, Hassall DG, Ancellin N, Patterson SD, Lobe DC, et al. 2007. Triglyceride:high- density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol 27:359-365. (Pubitemid 46143052)
41. Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, Watanabe M, Magoori K, Ioka RX, Tachibana K, et al. 2003. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 100:15924-15929.
42. Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, Matsumoto K, Nakamura T, Takahashi H, Okamoto E, et al. 1999. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 5:226-230. (Pubitemid 29068532)
43. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM. 2003. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113:159-170.
44. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T, Tokusashi Y, Miyokawa N, Nakamura K. 2004. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40:1222-1225.